Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir A Kulkarni

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Chemical Communications (Cambridge, England)|January 13, 2017
Reversible control of solubility using functionalized nanoparticlesSamir A Kulkarni, Allan S Myerson
Chemical Communications (Cambridge, England)|April 14, 2012
Isonicotinamide self-association: the link between solvent and polymorph nucleationSamir A Kulkarni, E S McGarrity, Hugo Meekes, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|September 27, 2014
Self-association during heterogeneous nucleation onto well-defined templatesSamir A Kulkarni, Cameron C Weber, Allan S Myerson, et al.
Organic Process Research & Development|August 8, 2023
Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19Christophe Allais, David Bernhardson, Adam R Brown, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Chemical Communications (Cambridge, England)|January 13, 2017
Reversible control of solubility using functionalized nanoparticlesSamir A Kulkarni, Allan S Myerson
Chemical Communications (Cambridge, England)|April 14, 2012
Isonicotinamide self-association: the link between solvent and polymorph nucleationSamir A Kulkarni, E S McGarrity, Hugo Meekes, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|September 27, 2014
Self-association during heterogeneous nucleation onto well-defined templatesSamir A Kulkarni, Cameron C Weber, Allan S Myerson, et al.
Organic Process Research & Development|August 8, 2023
Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19Christophe Allais, David Bernhardson, Adam R Brown, et al.
Pageof 1